Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2010

View Archived Issues

QTc interval is prolonged in myotonic dystrophy type 1 / News in Context

Phase II data show efficacy of Gilead Sciences' Quad anti-HIV regimen through 48 weeks

TransVax reduces cytomegalovirus viremia in phase II trial

SAR-707 reveals limitations of acyl-CoA desaturase inhibition in metabolic disorders

Chitosan-GP is efficacious in ongoing trial in patients with articular cartilage lesions

Acucela and Otsuka Pharma to codevelop and -promote OPA-6566 for glaucoma

Cylene begins phase I trial of CX-4945 in multiple myeloma

FDA grants orphan drug status for iCo-009 in visceral leishmaniasis

Phase III trial of Budesonide MMX in ulcerative colitis meets primary endpoint

Prefilled syringes of Relistor approved in U.S., E.U. and Canada

Medivation and Astellas begin phase III MDV-3100 trial in advanced prostate cancer

Astellas files for Japanese approval of darexaban for VTE prevention

Enrollment complete in phase IIa trial of XOMA-052 in type 2 diabetes

Zeria submits acotiamide for approval in Japan to treat functional dyspepsia

Unibioscreen claims novel cardiotonic steroid derivatives

Baxter obtains approval in Austria for Preflucel influenza vaccine

New voltage-gated potassium K(V)7.2/3 channel modulators described

Cleveland BioLabs reports on second safety study of CBLB-502

AstraZeneca begins enrollment in phase III OSKIRA program for fostamatinib in RA

Novel benzoxazinone derivatives claimed by NeuroSearch

Conbriza is approved in Spain for postmenopausal osteoporosis

Astellas and UMN Pharma enter definitive agreement for flu vaccines

Pieris, sanofi-aventis and Sanofi Pasteur to develop anticalin therapeutics

Astellas Pharma patents new 17-beta-HSD 5 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...